Leiden, The Netherlands, August 24, 2015 – Dutch clinical stage company DCPrime BV, dedicated to developing cancer vaccines based on its proprietary dendritic cell (DC) technology platform DCOne®, today announced that it has started a collaboration on the potential application of its lead product DCP-001 in Multiple Myeloma patients with Prof. Dr. David Avigan, Beth Israel Deaconess Medical Center, Dana Farber Cancer Center, Harvard.
The collaboration is currently in the pre-clinical stages, in preparation for a PoC study in Multiple Myeloma (MM) patients. Dr Avigan has already performed successful immune therapy studies with patient-derived DC-MM fusion vaccines in MM patients, and those have shown clear feasibility and clinical responses. The option to replace patient-derived DC by DC derived from a sustainable cell source is an attractive alternative, and DCP-001 is indeed derived from DCPrime’s DCOne® platform and developed as an off-the-shelf allogeneic DC vaccine. It consists of mature DC’s generated from DCPrime’s proprietary DCOne® cell line, originally derived from an Acute Myeloid Leukemia (AML) cell line. DCP-001 combines the properties of a DC vaccine with that of tumor cell vaccines that serve as antigen-delivery vehicles. Since DCP-001 is derived from an AML cell line, it endogenously expresses several defined leukemia antigens, including WT-1, PRAME, RHAMM, and MUC1. Therefore, DCP-001 has strong potential of being a vaccine for multi-targeted immunotherapy of several hematological malignancies in which these antigens have shown to be target for the immune system, including MM. The intended PoC study with MM patients is designed to determine both clinical and immunological responses to DCP-001.
Last updated: november 13, 2017